Japan· JP-3999016M1021
メトトレキサート
A methotrexate product containing メトトレキサート, registered in Japan by ファイザー, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Methotrexate is registered in 12 of 19 countries.
Countries holding a registration under ATC L01BA01 (methotrexate), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 7 of them publish a price we can compare per daily dose
Methotrexate · ATC L01BA01
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- メトトレキサート
- Manufacturer
- ファイザー
- Country
- Japan (JP)
- ATC code
- L01BA01
- ATC class
- Methotrexate
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
949 interactions on record for methotrexate.
Graded by severity as the source publishes them — 107 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Methotrexate · interactions on record
949 records
- 107 severe
- 466 moderate
- 17 minor
- 309 info
Most severe, free to view
- OmeprazoleA02BC01severe
- PantoprazoleA02BC02severe
- LansoprazoleA02BC03severe
- RabeprazoleA02BC04severe
50 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01BA01
Methotrexate, as other registers publish it.
- CanadaACH-METHOTREXATEACCORD HEALTHCARE INC
- CanadaAPO-METHOTREXATEAPOTEX INC
- NorwayEbetrexEBEWE Pharma Ges.m.b.H Nfg. KG
- FinlandEbetrexEbewe Pharma Ges.m.b.H. Nfg.KG
- BelgiumEbetrexat 10 mg/mlEbewe Pharma GesmbH Nfg KG
- BelgiumEbetrexat 20 mg/mlSandoz
- BelgiumEbetrexat 20 mg/mlSandoz
- BelgiumEbetrexat 20 mg/mlSandoz
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bcdd29c8-6ff6-44a0-8ddc-b80ab5867dd7 GET /v1/drugs/bcdd29c8-6ff6-44a0-8ddc-b80ab5867dd7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "２ｍｇ１カプセル",
"marks": "局",
"source": "mhlw",
"remarks": null,
"yj_code": "3999016M1021",
"category": "内用薬",
"price_yen": 77.9,
"generic_name": "メトトレキサート",
"product_name_jp": null,
"therapeutic_class": "3999",
"transitional_expiry": null
}See everything about methotrexate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.